skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

The treatment of chronic hepatitis B: Focus on adefovir-like antivirals

Review

(2502) Views  (459) Full article downloads

Authors: Hans Ludger Tillmann

Published Date September 2008 Volume 2008:4(4) Pages 797 - 802
DOI: http://dx.doi.org/10.2147/TCRM.S1965

Hans Ludger Tillmann

Medizinische Klinik und Poliklinik II, Universität Leipzig, Germany

Abstract: Several options for the treatment of hepatitis B have been licensed in the last years: interferon, pegylated interferon, lamivudine, adefovir, entecavir, and telbivudine. In addition tenofovir has been licensed in the EU and is expected to be licensed in the USA in 2008. The antivirals can be divided into “lamivudine-like” and “adefovir-like”, which clinically differ in their capacity to induce “YMDD” mutants, which are the hallmark of lamivudine resistance. The differing resistance profile makes them good combination partners, even in the absence of synergy in antiviral potency.

Keywords: adefovir, tenofovir, pradefovir, almefovir, antiviral therapy, hepatitis B








Readers of this article also read:

A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil®)
AAS, growth hormone, and insulin abuse: psychological and neuroendocrine effects
Postoperative mortality after inpatient surgery: Incidence and risk factors
Fospropofol disodium injection for the sedation of patients undergoing colonoscopy
Posaconazole in the management of refractory invasive fungal infections
Review of oral oxymorphone in the management of pain
Prevalence of risk factors, coronary and systemic atherosclerosis in abdominal aortic aneurysm: Comparison with high cardiovascular risk population
Diclofenac gel in the treatment of actinic keratoses
Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK
Erratum